View our Arixtra® Products

Arixtra® Quick Facts

  • Molecular mass: 1.728 D
  • Plasma half-life: 17-21h
  • Peak plasma time: 2-3 hours after subcutaneous injection
  • Bioavailability: 100% after subcutaneous injection
  • Composition: Different from Heparins, Fondaparinux is a pure, homogenous agent

Clinical Aspects of Arixtra®

Arixtra® (Fondaparinux sodium) is an anticoagulant drug from the group of heparinoids preventing coagulation similar to heparin. It enhances the inhibitory activity of antithrombin. In contrast to conventional heparin and low molecular heparins, fondaparinux is a synthetic, homogenous agent. Fondaparinux is the shortest active polysaccharide. It consists of only 5 subunits. This pentasaccharide is considered to have a low allergenic risk and does not bind to platelet factor 4 (PF4). The dose is indicated as gravimetric mass, e.g. mg, unlike heparins where the activity of factor Xa inhibition is indicated.

If monitoring of anticoagulation therapy or an individual dose setting is necessary, a functional anti-factor Xa chromogenic assay (e.g. Chromogenix Coamatic® Heparin) should be used. In this assay, plasma spiked with Arixtra® has to be used for generation of a standard curve.

Clinical or Research use of Arixtra®

  • Prophylaxis of deep vein thrombosis (DVT) in adult subjects undergoing major surgery on the lower extremities (hip or knee fracture or replacement)
  • Prophylaxis of deep vein thrombosis in adult subjects undergoing abdominal surgery who are at risk for thromboembolic complications
  • Prophylaxis of deep vein thrombosis in adult non-surgical subjects with elevated risk levels for DVT
  • Therapy of acute, symptomatic, spontaneous, superficial vein thrombosis of the lower extremities without deep vein thrombosis in adults

View our Arixtra® Products

Search this site for Arixtra®